Bridge Biotherapeutics, Inc

Bridge Biotherapeutics Inc. is a publicly traded clinical-stage biotech company based in the Republic of Korea with labs and offices in the U.S. Founded in 2015, Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics for disease indications with high unmet medical needs, including cancer, ulcerative colitis, and fibrotic diseases. The company's clinical pipeline includes BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis; BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF); and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.